新型降糖药物对2型糖尿病患者的肾脏获益及应用前景

糖尿病肾病是2型糖尿病患者常见微血管并发症之一，也是我国终末期肾病患者的常见病因。近年来多项随机对照试验发现，二肽基肽酶4抑制剂、钠-葡萄糖共转动蛋白2抑制剂、胰高血糖素样肽1受体激动剂等新型降糖药物除降糖作用之外，部分还具有肾脏保护作用，其中钠-葡萄糖共转动蛋白2抑制剂、胰高血糖素样肽1受体激动剂已被相关临床指南或专家共识推荐用于2型糖尿病患者合并慢性肾脏病患者，为临床预防和治疗糖尿病肾病、延缓糖尿病肾病进展提供了新选择。本文结合最新指南及临床试验总结、分析了新型降糖药物对2型糖尿病患者的肾脏获益，以期为临床更好地应用新型降糖药物提供参考。

Application Prospect and Renal Outcomes of Novel Antidiabetic Agents in Patients with Type 2 Diabetes

Diabetic nephropathy，a common microvascular complication of type 2 diabetes，has become one of the common causes of end-stage renal disease in China.Several randomized controlled studies conducted in recent years found that，some novel anti-diabetic agents including dipeptidyl peptidase-4 inhibitor，sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist，have significant renal protection outcomes beside hypoglycemia effect in patients with type 2 diabetes，moreover sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist were recommended by clinical guideline or consensus in the prevention and delay of diabetic kidney disease.This paper summarized and analyzed the outcome of novel anti-diabetic agents in renal protection outcomes in patients with type 2 diabetes based on recent clinical guidelines and related randomized controlled trials，in order to provide a reference for the better application of novel anti-diabetic agents in practice.